首页> 美国卫生研究院文献>NeuroRx >The Riluzole Derivative 2-Amino-6-trifluoromethylthio-benzothiazole (SKA-19) a Mixed KCa2 Activator and NaV Blocker is a Potent Novel Anticonvulsant
【2h】

The Riluzole Derivative 2-Amino-6-trifluoromethylthio-benzothiazole (SKA-19) a Mixed KCa2 Activator and NaV Blocker is a Potent Novel Anticonvulsant

机译:Riluzole衍生物2-氨基-6-三氟甲硫基苯并噻唑(SKA-19)混合的KCa2活化剂和NaV阻滞剂是一种有效的新型抗惊厥药

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Inhibitors of voltage-gated sodium channels (Nav) have been used as anticonvulsants since the 1940s, while potassium channel activators have only been investigated more recently. We here describe the discovery of 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a thioanalog of riluzole, as a potent, novel anticonvulsant, which combines the two mechanisms. SKA-19 is a use-dependent NaV channel blocker and an activator of small-conductance Ca2+-activated K+ channels. SKA-19 reduces action potential firing and increases medium afterhyperpolarization in CA1 pyramidal neurons in hippocampal slices. SKA-19 is orally bioavailable and shows activity in a broad range of rodent seizure models. SKA-19 protects against maximal electroshock-induced seizures in both rats (ED50 1.6 mg/kg i.p.; 2.3 mg/kg p.o.) and mice (ED50 4.3 mg/kg p.o.), and is also effective in the 6-Hz model in mice (ED50 12.2 mg/kg), Frings audiogenic seizure-susceptible mice (ED50 2.2 mg/kg), and the hippocampal kindled rat model of complex partial seizures (ED50 5.5 mg/kg). Toxicity tests for abnormal neurological status revealed a therapeutic index (TD50/ED50) of 6–9 following intraperitoneal and of 33 following oral administration. SKA-19 further reduced acute pain in the formalin pain model and raised allodynic threshold in a sciatic nerve ligation model. The anticonvulsant profile of SKA-19 is comparable to riluzole, which similarly affects NaV and KCa2 channels, except that SKA-19 has a ~4-fold greater duration of action owing to more prolonged brain levels. Based on these findings we propose that compounds combining KCa2 channel-activating and Nav channel-blocking activity exert broad-spectrum anticonvulsant and analgesic effects.Electronic supplementary materialThe online version of this article (doi:10.1007/s13311-014-0305-y) contains supplementary material, which is available to authorized users.
机译:自1940年代以来,电压门控钠通道(Nav)抑制剂一直用作抗惊厥药,而钾通道激活剂只是最近才被研究。我们在这里描述了2-氨基-6-三氟甲基硫代-苯并噻唑(SKA-19)的发现,利鲁唑的硫代类似物,作为一种强效的新型抗惊厥药,结合了两种机理。 SKA-19是一种与用途有关的NaV通道阻滞剂,是小电导Ca 2 + 激活的K + 通道的激活剂。 SKA-19减少动作电位放电并增加海马切片CA1锥体神经元的超极化后中等水平。 SKA-19具有口服生物利用度,并在广泛的啮齿动物癫痫发作模型中显示出活性。 SKA-19可防止大鼠(ED50 1.6 mg / kg ip; 2.3 mg / kg po)和小鼠(ED50 4.3 mg / kg po)的最大电击诱发癫痫发作,并且在小鼠的6 Hz模型中也有效(ED50 12.2 mg / kg),Frings音源性癫痫易感小鼠(ED50 2.2 mg / kg)和复杂部分性癫痫发作的海马点燃大鼠模型(ED50 5.5 mg / kg)。异常神经系统状况的毒性测试显示,腹膜内给药后的治疗指数(TD50 / ED50)为6-9,口服后为33。 SKA-19进一步减轻了福尔马林疼痛模型中的急性疼痛,并增加了坐骨神经结扎模型中的异常性疼痛阈值。 SKA-19的抗惊厥作用与利鲁唑相当,后者对NaV和KCa2通道的影响相似,但由于脑水平延长,SKA-19的作用持续时间延长了约4倍。基于这些发现,我们建议结合KCa2通道激活和Nav通道阻断活性的化合物发挥广谱抗惊厥和镇痛作用。电子补充材料本文的在线版本(doi:10.1007 / s13311-014-0305-y)包含补充材料,授权用户可以使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号